Modeling Human Interindividual Variability in Metabolism and Risk: The Example of 4‐Aminobiphenyl
- 1 April 1995
- journal article
- Published by Wiley in Risk Analysis
- Vol. 15 (2) , 205-213
- https://doi.org/10.1111/j.1539-6924.1995.tb00314.x
Abstract
We investigate, through modeling, the impact of interindividual heterogeneity in the metabolism of 4-aminobiphenyl (ABP) and in physiological factors on human cancer risk: A physiological pharmacokinetic model was used to quantify the time course of the formation of the proximate carcinogen, N-hydroxy-4-ABP and the DNA-binding of the active species in the bladder. The metabolic and physiologic model parameters were randomly varied, via Monte Carlo simulations, to reproduce interindividual variability. The sampling means for most parameters were scaled from values developed by Kadlubar et al. (Cancer Res., 51: 4371, 1991) for dogs; variances were obtained primarily from published human data (e.g., measurements of ABP N-oxidation, and arylamine N-acetylation in human liver tissue). In 500 simulations, theoretically representing 500 humans, DNA-adduct levels in the bladder of the most susceptible individuals are ten thousand times higher than for the least susceptible, and the 5th and 95th percentiles differ by a factor of 160. DNA binding for the most susceptible individual (with low urine pH, low N-acetylation and high N-oxidation activities) is theoretically one million-fold higher than for the least susceptible (with high urine pH, high N-acetylation and low N-oxidation activities). The simulations also suggest that the four factors contributing most significantly to interindividual differences in DNA-binding of ABP in human bladder are urine pH, ABP N-oxidation, ABP N-acetylation and urination frequency.Keywords
This publication has 31 references indexed in Scilit:
- Black (air-cured) and blond (flue-cured) tobacco cancer risk IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogensEuropean Journal Of Cancer, 1993
- Oral contraceptives stimulate the excretion of clofibric acid glucuronide in women and female ratsGeneral Pharmacology: The Vascular System, 1991
- The metabolism of 4-aminobiphenyl in rat. III. Urinary metabolites of 4-aminobiphenylXenobiotica, 1991
- Sulfotransferase pharmacogeneticsPharmacology & Therapeutics, 1990
- Precision and sensitivity of pharmacokinetic models for cancer risk assessment: Tetrachloroethylene in mice, rats, and humansToxicology and Applied Pharmacology, 1990
- Chemical Properties of Ultimate Carcinogenic Metabolites of Arylamines and ArylamidesPublished by American Chemical Society (ACS) ,1985
- Pharmacokinetic Scale-up: Accurate Prediction of Human Pharmacokinetic Profiles from Animal DataJournal of Pharmaceutical Sciences, 1985
- The association of the slow acetylator phenotype with bladder cancer.Journal of Medical Genetics, 1983
- Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretionChemico-Biological Interactions, 1980
- N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and DenmarkEnvironmental Health Perspectives, 1979